BIOMARIN PHARMACEUTICAL INC - 10-Q Filing
BioMarin Pharmaceutical reports Q3 2026 results following Amicus Therapeutics acquisition and Alesta Therapeutics transaction.
Tickers: $BMRN
BioMarin Pharmaceutical reports Q3 2026 results following Amicus Therapeutics acquisition and Alesta Therapeutics transaction.
Tickers: $BMRN